SCHEMBL29920528

SCHEMBL29920528

Cn1nccc1-c1ccc2c(c1)N(Cc1ccccc1)CC(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.56
IDH1 O75874 3/20 0.44
MAPK1 P28482 3/20 0.44
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
HDAC8 Q9BY41 3/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CREBBP Q92793 1/20 0.41
P2RX7 Q99572 1/20 0.41
RET P07949 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
OTUD7B Q6GQQ9 2/20 0.39
MAPK3 P27361 1/20 0.38
BRD4 O60885 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17798058 1.00 EPHX2 (0.56) EPHX2IDH1MAPK1CYP11B1CYP11B2
SCHEMBL1884654 0.78 CYP11B1 (0.65) EPHX2CYP11B1CYP11B2HDAC8HDAC2
SCHEMBL29920844 0.77 BRD4 (0.63) EPHX2CREBBPBRD4
SCHEMBL17798161 0.77 BRD4 (0.63) EPHX2CREBBPBRD4
SCHEMBL6541692 0.77 EPHX2 (0.62) EPHX2CYP11B1CYP11B2HDAC8HDAC2
SCHEMBL6541718 0.74 EPHX2 (0.70) EPHX2MAPK1HDAC8HDAC2HDAC6
SCHEMBL24200101 0.73 EPHX2 (1.00) EPHX2MAPK1HDAC8HDAC2HDAC6
SCHEMBL29778121 0.73 EPHX2 (1.00) EPHX2MAPK1HDAC8HDAC2HDAC6
SCHEMBL17131074 0.73 EPHX2 (0.51) EPHX2MAPK1CYP11B1CYP11B2RET
SCHEMBL14552638 0.67 EPHX2 (0.51) EPHX2MAPK1HDAC8HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11446306-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2022-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11446306-B2 Bicyclic bromodomain inhibitors BRD4, BRD3, BRD2 EPHX2 2831/4885IDH1 1000/4885MAPK1 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.